Dr Mark Blaskovich

Dr. Mark Blaskovich is a Senior Research Officer in the Institute for Molecular Biosciences (IMB) at the University of Queensland, with extensive medicinal chemistry expertise and over 15 years of industrial drug development experience. Previously, as Chief Operating Officer at Mimetica (Australia), he managed the drug discovery and development program for melanocortin-5 receptor antagonists leading to a compound currently in Phase II human trials for acne. In his role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate inhibitor of protein tyrosine phosphatase 1B, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs. Since 2010, Dr Blaskovich has been working on antimicrobial drug discovery projects at UQ, and is currently the Community for Open Antimicrobial Drug Discovery (CO-ADD) program coordinator for hit validation and chemistry. He has published over fifty articles and patents, including 'The Handbook on Syntheses of Amino Acids’.

Session 2 Chair: Antimicrobial drug discovery I
Monday 3  April

Session 6 Chair: Navigating the pipeline
Tuesday 4 April


Supported By